What a talar dome lesion actually is

An MRI report that mentions a 'talar dome lesion' can feel alarming — but the phrase simply means there is localised damage to the cartilage and the bone immediately beneath it on the upper surface of the talus, the ankle bone that bears the body's full weight with every step. Because cartilage has almost no blood supply of its own, even a small injury to this surface struggles to repair itself the way a muscle or ligament might.

These lesions are far more common than most people realise. Research suggests they are present in roughly 69–70% of significant ankle fractures and sprains, yet many are only picked up on MRI — sometimes weeks or months after the original injury, sometimes incidentally during imaging for an unrelated problem.

Medial versus lateral: why the location matters

The talar dome has two vulnerable zones, and where a lesion sits has direct implications for prognosis and treatment.

Medial lesions (inner dome) tend to be larger, deeper, and positioned further back on the dome. They often develop without an obvious traumatic event — a pattern of cumulative overload rather than a single impact — and some carry a degree of spontaneous healing potential.

Lateral lesions (outer dome) are almost always linked to a specific injury, typically an inversion sprain. They sit more anteriorly, tend to be smaller, but are more frequently displaced and less likely to settle without some form of intervention.

An MRI finding is not a diagnosis in itself

A talar dome lesion on a scan needs to be read alongside the patient's symptoms, functional limitations, and clinical examination. An incidental finding in someone with minimal pain and full function is a genuinely different situation from the same imaging appearance in someone with daily aching, swelling, and loss of confidence on uneven ground. One finding may warrant watchful waiting; the other warrants a structured plan. The scan is one input — not the verdict.

How to read the key findings in your MRI report

Radiology reports use shorthand that clinicians read fluently but that can feel opaque to everyone else. Four categories of finding are worth understanding, because together they tell the clinical story of how far a lesion has progressed and what it is doing to the surrounding bone.

Bone marrow oedema appears as a bright signal on T2-weighted images in the bone directly beneath the damaged area. Think of it as the bone's stress response — it signals active biological activity, and its presence indicates the area is still reactive rather than 'burnt out' and quiescent.

Cartilage surface changes range from mild swelling through surface fraying and fissuring to full-thickness loss or delamination. The extent of this determines how much structural cartilage remains to work with.

Subchondral integrity refers to the thin plate of bone sitting just beneath the cartilage. Micro-fractures, contour depression, sclerosis (hardening), and cyst formation each represent an escalating degree of structural compromise beneath the surface layer.

Fragment stability is where MRI earns its keep most clearly. If a fragment of bone or cartilage has separated, the single most important sign to look for is a fluid-filled halo — a bright T2 ring that completely encircles the fragment. This indicates instability and warrants prompt specialist review; it should not be left to resolve on its own.

What the staging numbers mean in practice

Clinicians use two shorthand systems — Hepple/Anderson and Berndt-Harty — to communicate severity quickly. The numbers run from early cartilage swelling at Stage 1 through to displaced loose fragments and subchondral cysts at the higher end. There is no need to memorise every label; the practical signal is that Stage 2b and above indicate chronicity, Stage 5 points to structural cyst formation, and Berndt-Harty Stages 3 and 4 (undisplaced and displaced loose fragment, respectively) are thresholds at which most protocols move directly towards surgical discussion rather than further conservative waiting. The scan's staging is a shorthand, not a sentence — it tells the clinician where on the spectrum to begin the conversation.

Lesion size also enters these discussions early: defects larger than approximately 1.5 cm² consistently behave differently from smaller ones and are independently flagged when weighing up management options.

Across all of this, MRI staging guides but does not replace clinical assessment. Symptom trajectory and functional status carry equal weight in any honest appraisal — two people with near-identical scans may genuinely need quite different responses.

When conservative care is the right first step

For many patients with a stable, small talar dome lesion — broadly those under 1.5 cm² without displaced fragments and with cartilage largely intact (Hepple Stages 1–2a) — structured non-operative management is a clinically legitimate first step, not a holding pattern. It gives the subchondral bone the biological conditions it needs to remodel and, in appropriate cases, can produce meaningful recovery.

The programme has two distinct phases. The first is protection: typically 4–6 weeks in a walking boot, reducing compressive load through the ankle while the bone settles. This is deliberate offloading with a defined end point, not simply an instruction to 'rest it and see'.

The second phase is active rehabilitation. Physiotherapy targets range of motion, peroneal and calf muscle strength, and proprioceptive retraining. The peroneal muscles are the primary dynamic stabilisers of the lateral ankle; when they fire slowly or weakly, the joint remains exposed to the micro-instability patterns that may have contributed to the lesion in the first place. Proprioceptive retraining — balance-board progressions, single-leg loading tasks — addresses the neuromuscular deficit that often persists long after pain subsides, reducing the risk of re-injury.

Bone stimulation, such as pulsed electromagnetic field therapy, is an established adjunct that some clinicians offer alongside physiotherapy, particularly where bone marrow oedema is prominent on the scan.

Medial lesions, as noted earlier, tend to carry somewhat greater spontaneous healing potential than lateral ones, which makes this population particularly suited to a conservative-first approach.

The full programme runs three to six months. That span reflects how long structured rehabilitation genuinely needs to produce a measurable clinical result — and crucially, progress should be reviewed at intervals. If symptoms are not improving in line with expectations, the question of escalation is assessed actively rather than deferred further.

Signs your lesion may need more than conservative care

Three months into a boot-and-physio programme with little to show for it is, on its own, a clear prompt to go back for specialist review. Six months of structured, supervised conservative care without meaningful improvement in pain or function is the primary time-based threshold that most clinical protocols use to move the conversation towards surgical options. That is not a failure of treatment — it is the programme working as intended, providing a defined window to assess whether the biology is responding.

Some symptoms, however, should not wait six months.

Mechanical symptoms — locking, catching, clicking, or sudden giving way — are an urgent flag. These are not simply pain in a different key; they suggest a loose or unstable fragment is moving within the joint, potentially damaging surrounding cartilage with every step. If these develop at any point during conservative care, prompt specialist review is warranted rather than continuing to wait.

Imaging findings that change the picture

Not every MRI result supports a full conservative trial. Several findings, seen at baseline or on follow-up imaging, indicate that escalation is worth discussing earlier:

• Berndt-Harty Stages 3 or 4 — a detached or displaced fragment has already separated from the underlying bone; conservative loading is unlikely to reattach it.
• Hepple Stage 5 — large subchondral cysts reflect structural bone loss beneath the cartilage surface, a degree of compromise that offloading alone rarely reverses.
• Worsening bone marrow oedema on follow-up MRI despite adherence to the conservative programme suggests the bone is not settling; it is escalating.
• Lesion area above approximately 1.5 cm² at baseline — as discussed in relation to staging, these defects behave differently and most protocols flag them for earlier surgical discussion rather than a prolonged conservative trial.
• Displaced lateral lesions — lateral lesions that present with displacement carry a lower likelihood of healing without intervention and should be assessed for early escalation rather than defaulting to conservative management.

Escalation means specialist assessment, not an automatic commitment to surgery. The next step is a clinical conversation about options — which may include surgical, biological, or combined approaches — based on the full picture of imaging, symptoms, and function.

Treatment options when conservative care is not enough

Once conservative care has been given a fair trial without adequate improvement, the choice of next step depends on lesion size, subchondral status, and cartilage integrity — no single technique suits every presentation.

Injectable collagen scaffold (outpatient, ultrasound-guided)

For contained defects where the cartilage surface is broadly preserved, an injectable collagen scaffold offers a matrix-induced chondrogenesis approach — recruiting the body's own progenitor cells to build new tissue within the defect — delivered as an ultrasound-guided outpatient injection, without theatre or arthroscopy. This positions it at the least-invasive end of the escalation ladder, between physiotherapy and arthroscopic surgery, for appropriately selected patients.

Arthroscopic microfracture

First-line surgery for small primary lesions perforates the subchondral bone to stimulate a fibrocartilage repair response. Published series report approximately 85% short-to-medium-term success for defects under 1.5 cm², though fibrocartilage is biomechanically inferior to native hyaline cartilage and longer-term deterioration rates rise with larger defects. A 2026 paper revisiting three decades of surgical evolution has reconsidered microfracture as a continuing primary option.

Retrograde drilling and LDFF

Where the overlying cartilage remains structurally intact and the problem is primarily subchondral, retrograde drilling avoids breaching the cartilage surface. The arthroscopic LDFF technique — lift, drill, fill, fix — is a valid alternative for primary defects where fragment stabilisation is the goal.

OATS (osteochondral autograft transfer)

For medium-to-large or cystic defects, OATS transfers a plug of genuine hyaline cartilage and underlying bone from a lower-load donor site. MRI fill scores and subchondral cyst rates compare favourably with microfracture, though a 2024 comparative study found functional outcomes broadly similar between the two techniques. Complication rates across OATS series range from 3.7% to 59%, and donor-site morbidity warrants honest discussion before surgery.

Osteoperiosteal autograft

Reserved for large (>1.5 cm²) or recurrent OLTs, this combines bone graft with periosteal patch. In a series of 30 patients treated with this approach, ankle function scores on a 100-point scale (where scores below 50 reflect significant limitation in daily activity) rose from roughly 41 to 95, and pain scores out of 10 fell from 7 to under 0.5 — from near-constant pain to near-none at final follow-up.

Treatment selection is genuinely individualised. Lesion size, depth, subchondral involvement, activity demands, and prior procedures all shape the recommendation; specialist assessment weighs these variables together rather than applying a fixed algorithm.

Getting the right assessment in London

Recognising yourself in the escalation triggers above — plateauing after months of physio, mechanical symptoms that won't settle, or an MRI report you cannot fully interpret — is usually the point at which a specialist consultation adds the most value.

What that consultation actually involves is straightforward: a clinician reviews your imaging in the context of your symptoms and functional limitations, not in isolation. Staging alone does not determine management; the conversation also covers what you can no longer do, how long things have been this way, and what your goals are. The output is a management plan — which may be continued conservative care, a biological or injection-based approach, or a surgical referral — rather than an automatic commitment to the operating theatre.

For patients where a contained defect is the primary problem and the cartilage surface is broadly preserved, the London Cartilage Clinic on Harley Street offers ChondroFiller injection — an injectable collagen scaffold delivered as an ultrasound-guided outpatient procedure — as one option within that broader discussion. Details and appointment booking are at londoncartilage.com.

1. [1] Anatomical insights into medial-sided talar dome OCLs using MRI measurements (2024). (2024). https://doi.org/10.1177/02841851241292814 https://doi.org/10.1177/02841851241292814
2. [2] Staging of Osteochondral Lesions of the Talus: MRI and Cone Beam CT (Posadzy 2017). (2017). https://doi.org/10.5334/jbr-btr.1377 https://doi.org/10.5334/jbr-btr.1377
3. [3] Autologous bone graft and periosteal patch for large and recurrent talar osteochondral defect (2025). (2025). https://doi.org/10.1016/j.jcot.2025.103132 https://doi.org/10.1016/j.jcot.2025.103132